drugset / Trial / NCT07126782
The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of allogeneic γδ T cells in patients with MRD-positive AML after allo-HSCT.
Timeline
- Start
- 2025-07-20
- Primary completion
- 2027-12-20
- Completion
- 2028-07-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ex-vivo expanded allogeneic γδT cells | Cell therapy | 2e+08 cells/kg | — |
| Subject | Ex-vivo expanded allogeneic γδT cells | Cell therapy | 4e+08 cells/kg | — |